Home The Word Brain Fast Track My Amedeo FAQ About Flying Publisher   

Fast Track

Ear2MemoryFree App | Free PDF | Web
Learning languages on your smartphone
By BSK

Free Abstracts

  Breast Cancer

  Free Subscription


Articles published in Int J Cancer

Retrieve available abstracts of 75 articles:
HTML format
Text format



Single Articles


    March 2017
  1. MARTINEZ VG, Crown J, Porter RK, O'Driscoll L, et al
    Neuromedin U alters bioenergetics and expands the cancer stem cell phenotype in HER2-positive breast cancer.
    Int J Cancer. 2017 Mar 24. doi: 10.1002/ijc.30705.
    PubMed     Text format     Abstract available


  2. BRINTON LA, Awuah B, Clegg-Lamptey JN, Wiafe-Addai B, et al
    Design considerations for identifying breast cancer risk factors in a population-based study in Africa.
    Int J Cancer. 2017 Mar 13. doi: 10.1002/ijc.30688.
    PubMed     Text format     Abstract available


  3. PARK YM, White AJ, Nichols HB, O'Brien KM, et al
    The association between metabolic health, obesity phenotype and the risk of breast cancer.
    Int J Cancer. 2017 Mar 7. doi: 10.1002/ijc.30684.
    PubMed     Text format     Abstract available


  4. GADEYNE S, Menvielle G, Kulhanova I, Bopp M, et al
    The turn of the gradient? Educational differences in breast cancer mortality in 18 European populations during the 2000s.
    Int J Cancer. 2017 Mar 7. doi: 10.1002/ijc.30685.
    PubMed     Text format     Abstract available


  5. WANG J, Shidfar A, Ivancic D, Ranjan M, et al
    Overexpression of lipid metabolism genes and PBX1 in the contralateral breasts of women with estrogen receptor-negative breast cancer.
    Int J Cancer. 2017 Mar 6. doi: 10.1002/ijc.30680.
    PubMed     Text format     Abstract available


  6. VAN DEN BRANDT PA, Schulpen M
    Mediterranean diet adherence and risk of postmenopausal breast cancer: results of a cohort study and meta-analysis.
    Int J Cancer. 2017 Mar 5. doi: 10.1002/ijc.30654.
    PubMed     Text format     Abstract available


    February 2017
  7. STROTBEK M, Schmid S, Sanchez-Gonzalez I, Boerries M, et al
    miR-181 elevates Akt signaling by co-targeting PHLPP2 and INPP4B phosphatases in luminal breast cancer.
    Int J Cancer. 2017 Feb 22. doi: 10.1002/ijc.30661.
    PubMed     Text format     Abstract available


  8. LIN X, Chen W, Wei F, Zhou BP, et al
    POMC maintains tumor-initiating properties of tumor tissue-derived long-term-cultured breast cancer stem cells.
    Int J Cancer. 2017 Feb 18. doi: 10.1002/ijc.30658.
    PubMed     Text format     Abstract available


    January 2017
  9. ROSNER B, Eliassen AH, Toriola AT, Chen WY, et al
    Weight and weight changes in early adulthood and later breast cancer risk.
    Int J Cancer. 2017 Jan 30. doi: 10.1002/ijc.30627.
    PubMed     Text format     Abstract available


  10. HALPERN N, Sonnenblick A, Uziely B, Divinsky L, et al
    Oncotype Dx recurrence score among BRCA1/2 germline mutation carriers with hormone receptors positive breast cancer.
    Int J Cancer. 2017 Jan 24. doi: 10.1002/ijc.30616.
    PubMed     Text format     Abstract available


    December 2016
  11. BENNETT L, Quinn J, McCall P, Mallon EA, et al
    High IKKalpha expression is associated with reduced time to recurrence and cancer specific survival in oestrogen receptor (ER)-positive breast cancer.
    Int J Cancer. 2016 Dec 22. doi: 10.1002/ijc.30578.
    PubMed     Text format     Abstract available


  12. XU W, Jia G, Cai N, Huang S, et al
    A 16 Yin Yang Gene Expression Ratio Signature for ER+/Node- Breast Cancer.
    Int J Cancer. 2016 Dec 7. doi: 10.1002/ijc.30556.
    PubMed     Text format     Abstract available


  13. CHEN S, Wang RX, Liu Y, Yang WT, et al
    PD-L1 expression of the residual tumor serves as a prognostic marker in local advanced breast cancer after neoadjuvant chemotherapy.
    Int J Cancer. 2016 Dec 7. doi: 10.1002/ijc.30552.
    PubMed     Text format     Abstract available


  14. MATEJCIC M, de Batlle J, Ricci C, Biessy C, et al
    Biomarkers of folate and vitamin B12 and breast cancer risk: Report from the EPIC cohort.
    Int J Cancer. 2016 Dec 1. doi: 10.1002/ijc.30536.
    PubMed     Text format     Abstract available


    November 2016
  15. KARASNEH RA, Murray LJ, Cardwell CR
    Cardiac glycosides and breast cancer risk: A systematic review and meta-analysis of observational studies.
    Int J Cancer. 2016 Nov 15. doi: 10.1002/ijc.30520.
    PubMed     Text format     Abstract available


  16. VAN LUIJT PA, Heijnsdijk EA, de Koning HJ
    Cost-effectiveness of the Norwegian breast cancer screening program.
    Int J Cancer. 2016 Nov 11. doi: 10.1002/ijc.30513.
    PubMed     Text format     Abstract available


  17. YANG H, Brand JS, Fang F, Chiesa F, et al
    Time-dependent risk of depression, anxiety and stress-related disorders in patients with invasive and in-situ breast cancer.
    Int J Cancer. 2016 Nov 11. doi: 10.1002/ijc.30514.
    PubMed     Text format     Abstract available


  18. BODELON C, Oh H, Chatterjee N, Garcia-Closas M, et al
    Association between breast cancer genetic susceptibility variants and terminal duct lobular unit involution of the breast.
    Int J Cancer. 2016 Nov 9. doi: 10.1002/ijc.30512.
    PubMed     Text format     Abstract available


  19. BHUSARI P, Vatsa R, Singh G, Parmar M, et al
    Development of Lu-177-trastuzumab for radioimmunotherapy of HER2 expressing breast cancer and its feasibility assessment in breast cancer patients.
    Int J Cancer. 2016 Nov 3. doi: 10.1002/ijc.30500.
    PubMed     Text format     Abstract available


    October 2016
  20. FERRONI P, Santilli F, Cavaliere F, Simeone P, et al
    Oxidant stress as a major determinant of platelet activation in invasive breast cancer.
    Int J Cancer. 2016 Oct 26. doi: 10.1002/ijc.30488.
    PubMed     Text format     Abstract available


    September 2016
  21. SIMONSSON M, Bjorner S, Markkula A, Nodin B, et al
    The prognostic impact of COX-2 expression in breast cancer depends on oral contraceptive history, preoperative NSAID use, and tumor size.
    Int J Cancer. 2016 Sep 15. doi: 10.1002/ijc.30432.
    PubMed     Text format     Abstract available


  22. VAN DER WAAL D, Ripping TM, Verbeek AL, Broeders MJ, et al
    Breast cancer screening effect across breast density strata: A case-control study.
    Int J Cancer. 2016 Sep 15. doi: 10.1002/ijc.30430.
    PubMed     Text format     Abstract available


  23. STRAND F, Humphreys K, Eriksson M, Li J, et al
    Longitudinal fluctuation in mammographic percent density differentiates between interval and screen-detected breast cancer.
    Int J Cancer. 2016 Sep 12. doi: 10.1002/ijc.30427.
    PubMed     Text format     Abstract available


  24. SYNNOTT NC, Murray A, McGowan PM, Kiely M, et al
    Mutant p53: A Novel Target for the Treatment of Patients with Triple-Negative Breast Cancer?
    Int J Cancer. 2016 Sep 12. doi: 10.1002/ijc.30425.
    PubMed     Text format     Abstract available


  25. ROMIEU I, Ferrari P, Chajes V, de Batlle J, et al
    Fiber intake modulates the association of alcohol intake with breast cancer.
    Int J Cancer. 2016 Sep 6. doi: 10.1002/ijc.30415.
    PubMed     Text format     Abstract available


  26. HE W, Lindstrom LS, Hall P, Czene K, et al
    Cause-specific mortality in women with breast cancer in situ.
    Int J Cancer. 2016 Sep 4. doi: 10.1002/ijc.30413.
    PubMed     Text format     Abstract available


    August 2016
  27. NOMURA SJ, Dash C, Rosenberg L, Yu J, et al
    Adherence to diet, physical activity and body weight recommendations and breast cancer incidence in the Black Women's Health Study.
    Int J Cancer. 2016 Aug 31. doi: 10.1002/ijc.30410.
    PubMed     Text format     Abstract available


  28. FRY EA, Taneja P, Inoue K
    Oncogenic and tumor-suppressive mouse models for breast cancer engaging HER2/neu.
    Int J Cancer. 2016 Aug 23. doi: 10.1002/ijc.30399.
    PubMed     Text format     Abstract available


  29. KIISKI JI, Fagerholm R, Tervasmaki A, Pelttari LM, et al
    FANCM c.5101C>T mutation associates with breast cancer survival and treatment outcome.
    Int J Cancer. 2016 Aug 20. doi: 10.1002/ijc.30394.
    PubMed     Text format     Abstract available


  30. KIM HJ, Min A, Im SA, Jang H, et al
    Anti-tumor Activity of the ATR Inhibitor AZD6738 in HER2 positive Breast Cancer Cells.
    Int J Cancer. 2016 Aug 8. doi: 10.1002/ijc.30373.
    PubMed     Text format     Abstract available


  31. LI J, Humphreys K, Eriksson M, Dar H, et al
    Worse quality of life in young and recently-diagnosed breast cancer survivors compared to female survivors of other cancers: A cross-sectional study.
    Int J Cancer. 2016 Aug 3. doi: 10.1002/ijc.30370.
    PubMed     Text format     Abstract available


    July 2016
  32. DARLIX A, Lamy PJ, Lopez-Crapez E, Braccini AL, et al
    Serum NSE, MMP-9 and HER2 extra-cellular domain are associated with brain metastases in metastatic breast cancer patients: Predictive biomarkers for brain metastases?
    Int J Cancer. 2016 Jul 27. doi: 10.1002/ijc.30290.
    PubMed     Text format     Abstract available


  33. CADEAU C, Fournier A, Mesrine S, Clavel-Chapelon F, et al
    Postmenopausal breast cancer risk and interactions between body mass index, menopausal hormone therapy use, and vitamin D supplementation: Evidence from the E3N cohort.
    Int J Cancer. 2016 Jul 23. doi: 10.1002/ijc.30282.
    PubMed     Text format     Abstract available


  34. KIM SB, Wildiers H, Krop IE, Smitt M, et al
    Relationship between tumor biomarkers and efficacy in TH3RESA, a phase III study of trastuzumab emtansine (T-DM1) versus treatment of physician's choice in previously treated HER2-positive advanced breast cancer.
    Int J Cancer. 2016 Jul 18. doi: 10.1002/ijc.30276.
    PubMed     Text format     Abstract available


  35. AYRAULT-PIAULT S, Grosclaude P, Daubisse-Marliac L, Pascal J, et al
    Are disparities of waiting times for breast cancer care related to socio-economic factors? A regional population-based study (France).
    Int J Cancer. 2016 Jul 12. doi: 10.1002/ijc.30266.
    PubMed     Text format     Abstract available


  36. INOUE K, Fry EA
    Aberrant splicing of the DMP1-ARF-MDM2-p53 pathway in cancer.
    Int J Cancer. 2016;139:33-41.
    PubMed     Text format     Abstract available


    June 2016
  37. ABREU MH, Abreu PH, Afonso N, Pereira D, et al
    Patterns of recurrence and treatment in male breast cancer: A clue to prognosis?
    Int J Cancer. 2016 Jun 9. doi: 10.1002/ijc.30225.
    PubMed     Text format     Abstract available


    May 2016
  38. MANTHRAVADI S, Shrestha A, Madhusudhana S
    Impact of statin use on cancer recurrence and mortality in breast cancer: A systematic review and meta-analysis.
    Int J Cancer. 2016 May 13. doi: 10.1002/ijc.30185.
    PubMed     Text format     Abstract available


  39. JOYCE DP, Kerin MJ, Dwyer RM
    Exosome-encapsulated microRNAs as circulating biomarkers for breast cancer.
    Int J Cancer. 2016 May 11. doi: 10.1002/ijc.30179.
    PubMed     Text format     Abstract available


    April 2016
  40. LIU Y, Tobias DK, Sturgeon KM, Rosner B, et al
    Physical activity from menarche to first pregnancy and risk of breast cancer.
    Int J Cancer. 2016 Apr 30. doi: 10.1002/ijc.30167.
    PubMed     Text format     Abstract available


  41. HIS M, Fagherazzi G, Mesrine S, Boutron-Ruault MC, et al
    Pre-diagnostic body size and breast cancer survival in the E3N cohort study.
    Int J Cancer. 2016 Apr 22. doi: 10.1002/ijc.30158.
    PubMed     Text format     Abstract available


  42. SHI J, Zhang Y, Zheng W, Michailidou K, et al
    Fine-scale mapping of 8q24 locus identifies multiple independent risk variants for breast cancer.
    Int J Cancer. 2016 Apr 18. doi: 10.1002/ijc.30150.
    PubMed     Text format     Abstract available


  43. BU R, Siraj AK, Al-Obaisi KA, Beg S, et al
    Identification of Novel BRCA Founder Mutations in Middle Eastern Breast Cancer Patients Using Capture and Sanger Sequencing Analysis.
    Int J Cancer. 2016 Apr 15. doi: 10.1002/ijc.30143.
    PubMed     Text format     Abstract available


  44. HAAKENSEN VD, Nygaard V, Greger L, Aure MR, et al
    Subtype-specific micro-RNA expression signatures in breast cancer progression.
    Int J Cancer. 2016 Apr 15. doi: 10.1002/ijc.30142.
    PubMed     Text format     Abstract available


  45. LASHAM A, Mehta SY, Fitzgerald SJ, Woolley AG, et al
    A novel EGR-1 dependent mechanism for YB-1 modulation of paclitaxel response in a triple negative breast cancer cell line.
    Int J Cancer. 2016 Apr 12. doi: 10.1002/ijc.30137.
    PubMed     Text format     Abstract available


  46. KUIJER A, Drukker CA, Elias SG, Smorenburg CH, et al
    Changes over time in the impact of gene-expression profiles on the administration of adjuvant chemotherapy in estrogen receptor positive early stage breast cancer patients - a nationwide study.
    Int J Cancer. 2016 Apr 8. doi: 10.1002/ijc.30132.
    PubMed     Text format     Abstract available


  47. AMOURY M, Mladenov R, Nachreiner T, Pham AT, et al
    A novel approach for targeted elimination of CSPG4-positive triple-negative breast cancer cells using a MAP tau-based fusion protein.
    Int J Cancer. 2016 Apr 1. doi: 10.1002/ijc.30119.
    PubMed     Text format     Abstract available


    March 2016
  48. SEGNAN N, Minozzi S, Armaroli P, Cinquini M, et al
    Epidemiologic evidence of slow growing, non-progressive or regressive breast cancer: a systematic review.
    Int J Cancer. 2016 Mar 23. doi: 10.1002/ijc.30105.
    PubMed     Text format     Abstract available


  49. SUNG H, Rosenberg PS, Chen WQ, Hartman M, et al
    The impact of breast cancer-specific birth-cohort effects among younger and older Chinese populations.
    Int J Cancer. 2016 Mar 17. doi: 10.1002/ijc.30095.
    PubMed     Text format     Abstract available


  50. MORDUKHOVICH I, Beyea J, Herring AH, Hatch M, et al
    Polymorphisms in DNA Repair Genes, Traffic-Related Polycyclic Aromatic Hydrocarbon Exposure, and Breast Cancer Incidence.
    Int J Cancer. 2016 Mar 4. doi: 10.1002/ijc.30079.
    PubMed     Text format     Abstract available


  51. SCHOUTEN PC, Gluz O, Harbeck N, Mohrmann S, et al
    BRCA1-like profile predicts benefit of tandem high dose epirubicin-cyclophospamide-thiotepa in high risk breast cancer patients randomized in the WSG-AM01 trial.
    Int J Cancer. 2016 Mar 4. doi: 10.1002/ijc.30078.
    PubMed     Text format     Abstract available


  52. CONSOLINO L, Longo DL, Dastru W, Cutrin JC, et al
    Functional imaging of the angiogenic switch in a transgenic mouse model of human breast cancer by Dynamic Contrast Enhanced Magnetic Resonance Imaging (DCE-MRI).
    Int J Cancer. 2016 Mar 3. doi: 10.1002/ijc.30073.
    PubMed     Text format     Abstract available


    February 2016
  53. RAIMONDI S, Botteri E, Munzone E, Cipolla C, et al
    Use of beta-blockers, angiotensin-converting enzyme inhibitors and angiotensin receptor blockers and breast cancer survival: Systematic review and meta-analysis.
    Int J Cancer. 2016 Feb 24. doi: 10.1002/ijc.30062.
    PubMed     Text format     Abstract available


  54. BHUTIA SK, Behera B, Das DN, Mukhopadhyay S, et al
    Abrus agglutinin is a potent anti-proliferative and anti-angiogenic agent in human breast cancer.
    Int J Cancer. 2016 Feb 23. doi: 10.1002/ijc.30055.
    PubMed     Text format     Abstract available


    January 2016
  55. HARRIS HR, Bergkvist L, Wolk A
    Adherence to the world cancer research fund/american institute for cancer research recommendations and breast cancer risk.
    Int J Cancer. 2016 Jan 25. doi: 10.1002/ijc.30015.
    PubMed     Text format     Abstract available


  56. CASEY MC, Sweeney KJ, Andrew Lawrence Brown J, Kerin MJ, et al
    Exploring circulating microRNA in the Neoadjuvant Treatment of Breast Cancer.
    Int J Cancer. 2016 Jan 12. doi: 10.1002/ijc.29985.
    PubMed     Text format     Abstract available


  57. NOMURA SJ, Inoue-Choi M, Lazovich D, Robien K, et al
    WCRF/AICR recommendation adherence and breast cancer incidence among postmenopausal women with and without non-modifiable risk factors.
    Int J Cancer. 2016 Jan 12. doi: 10.1002/ijc.29994.
    PubMed     Text format     Abstract available


  58. WOODS LM, Rachet B, O'Connell DL, Lawrence G, et al
    Are international differences in breast cancer survival between Australia and England present amongst both screen-detected women and non-screen-detected women? Survival estimates for women diagnosed in West Midlands and New South Wales 1997-2006.
    Int J Cancer. 2016 Jan 12. doi: 10.1002/ijc.29984.
    PubMed     Text format     Abstract available


  59. WOODS LM, Rachet B, O'Connell D, Lawrence G, et al
    Impact of deprivation on breast cancer survival among women eligible for mammographic screening in the West Midlands (UK) and New South Wales (Australia): Women diagnosed 1997-2006.
    Int J Cancer. 2016 Jan 12. doi: 10.1002/ijc.29983.
    PubMed     Text format     Abstract available


    December 2015
  60. PENG C, Wallwiener M, Rudolph A, Cuk K, et al
    Plasma Hyaluronic Acid level as a Prognostic and Monitoring Marker of Metastatic Breast Cancer.
    Int J Cancer. 2015 Dec 19. doi: 10.1002/ijc.29975.
    PubMed     Text format     Abstract available


  61. SISTI JS, Collins LC, Beck AH, Tamimi RM, et al
    Reproductive risk factors in relation to molecular subtypes of breast cancer: Results from the Nurses' Health Studies.
    Int J Cancer. 2015 Dec 18. doi: 10.1002/ijc.29968.
    PubMed     Text format     Abstract available


  62. CAI H, Zhang Y, Han TK, Everett RS, et al
    Cation-selective transporters are critical to the ampk-mediated antiproliferative effects of metformin in human breast cancer cells.
    Int J Cancer. 2015 Dec 15. doi: 10.1002/ijc.29965.
    PubMed     Text format     Abstract available


  63. YAO S, Haddad SA, Hu Q, Liu S, et al
    Genetic variations in vitamin D-related pathways and breast cancer risk in African American women in the AMBER Consortium.
    Int J Cancer. 2015 Dec 9. doi: 10.1002/ijc.29954.
    PubMed     Text format     Abstract available


  64. NABHOLTZ JM, Chalabi N, Radosevic-Robin N, Dauplat MM, et al
    Multicentric neoadjuvant pilot phase II study of cetuximab combined with docetaxel in operable triple negative breast cancer.
    Int J Cancer. 2015 Dec 9. doi: 10.1002/ijc.29952.
    PubMed     Text format     Abstract available


  65. OBI N, Heinz J, Seibold P, Vrieling A, et al
    Relationship between menopausal hormone therapy and mortality after breast cancer.
    Int J Cancer. 2015 Dec 9. doi: 10.1002/ijc.29951.
    PubMed     Text format     Abstract available


  66. FIELD S, Uyttenhove C, Stroobant V, Cheou P, et al
    Novel highly specific anti-periostin antibodies uncover the functional importance of the fascilin 1-1 domain and highlight preferential expression of periostin in aggressive breast cancer.
    Int J Cancer. 2015 Dec 1. doi: 10.1002/ijc.29946.
    PubMed     Text format     Abstract available


    November 2015
  67. NECHUTA S, Chen WY, Cai H, Poole EM, et al
    A pooled analysis of post-diagnosis lifestyle factors in association with late estrogen-receptor positive breast cancer prognosis.
    Int J Cancer. 2015 Nov 25. doi: 10.1002/ijc.29940.
    PubMed     Text format     Abstract available


  68. SALAGAME U, Banks E, Sitas F, Canfell K, et al
    Menopausal Hormone Therapy use and breast cancer risk in Australia: Findings from the New South Wales Cancer Lifestyle and EvAluation of Risk (CLEAR) study.
    Int J Cancer. 2015 Nov 24. doi: 10.1002/ijc.29942.
    PubMed     Text format     Abstract available


  69. CAO Y, Hou L, Wang W
    Dietary total fat and fatty acids intake, serum fatty acids and risk of breast cancer: A meta-analysis of prospective cohort studies.
    Int J Cancer. 2015 Nov 23. doi: 10.1002/ijc.29938.
    PubMed     Text format     Abstract available


  70. HIRAGA T, Ito S, Nakamura H
    EpCAM expression in breast cancer cells is associated with enhanced bone metastasis formation.
    Int J Cancer. 2015 Nov 18. doi: 10.1002/ijc.29921.
    PubMed     Text format     Abstract available


  71. BLEYER A, Baines C, Miller AB
    Impact of Screening Mammography on Breast Cancer Mortality.
    Int J Cancer. 2015 Nov 12. doi: 10.1002/ijc.29925.
    PubMed     Text format     Abstract available


  72. BANERJEE K, Resat H
    Constitutive activation of STAT3 in breast cancer cells: A review.
    Int J Cancer. 2015 Nov 11. doi: 10.1002/ijc.29923.
    PubMed     Text format     Abstract available


  73. RIPPING TM, Hubbard RA, Otten JD, den Heeten GJ, et al
    Towards personalized screening: Cumulative risk of breast cancer screening outcomes in women with and without a first-degree relative with a history of breast cancer.
    Int J Cancer. 2015 Nov 4. doi: 10.1002/ijc.29912.
    PubMed     Text format     Abstract available


    October 2015
  74. LIN W, Ren FM, Ren ZF
    The contribution of radiotherapy to subsequent thyroid cancer risk may be confined to a subgroup of breast cancer patients.
    Int J Cancer. 2015 Oct 30. doi: 10.1002/ijc.29907.
    PubMed     Text format    


  75. SUN LM, Lin CL, Liang JA, Kao CH, et al
    Authors' reply to Radiotherapy did not increase thyroid cancer risk among women with breast cancer: A nationwide population-based cohort study.
    Int J Cancer. 2015 Oct 30. doi: 10.1002/ijc.29906.
    PubMed     Text format    


Thank you for your interest in scientific medicine.


AMEDEO Breast Cancer is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: